ライフサイエンスコーパス: pruritus

1 ogy Life Quality Index, Numeric Rating Scale pruritus).

2 tients with primary biliary cholangitis with pruritus.

3 1 patient discontinued ribavirin because of pruritus.

4 iary cholangitis, is largely ineffective for pruritus.

5 nistic research in patients with cholestatic pruritus.

6 vels in the systemic circulation and improve pruritus.

7 sensory network is thought to contribute to pruritus.

8 frequent AEs were throat irritation and oral pruritus.

9 lled, cross-over trial for PBC patients with pruritus.

10 rse events were mild injection-site pain and pruritus.

11 esented with a 2-week history of generalized pruritus.

12 ng fatigue, insomnia, irritability, and rash/pruritus.

13 of sweat ducts and leads to inflammation and pruritus.

14 ht be developed for treatment of cholestatic pruritus.

15 o participate and were found to have chronic pruritus.

16 arks of severe inflammation and allergy with pruritus.

17 s in either group were nausea, diarrhea, and pruritus.

18 in clinical signs and symptoms in particular pruritus.

19 rom B5-I neurons, is a key neuromodulator of pruritus.

20 centrations of bile acids (BAs) and profound pruritus.

21 n adverse events were headache, fatigue, and pruritus.

22 ted to participate; 405 of these had chronic pruritus.

23 f patients reported a deterioration in their pruritus.

24 clinical evaluation and treatment of chronic pruritus.

25 t the severity of neuraxial-morphine-induced pruritus.

26 teria, and more likely to report fatigue and pruritus.

27 useful for the management of opioid-induced pruritus.

28 skin is thought to contribute to cholestatic pruritus.

29 postoperative nausea and vomiting (PONV) and pruritus.

30 associated with inflammation and persistent pruritus.

31 o be effective for reducing the incidence of pruritus.

32 ly initiates the process that causes intense pruritus.

33 oach for histaminergic and non-histaminergic pruritus.

34 inate may be useful for treating established pruritus.

35 hould be considered in elderly patients with pruritus.

36 ing mouse TGR5), which exhibited spontaneous pruritus.

37 ropathy should be considered when evaluating pruritus.

38 ed syndrome, which is associated with severe pruritus.

39 rier dysfunction etiology of AD with chronic pruritus.

40 erate-to-severe prurigo nodularis and severe pruritus.

41 lergic contact dermatitis-associated chronic pruritus.

42 provements in clinical severity measures and pruritus.

43 ryness, psoriasis, and urticaria, can elicit pruritus.

44 signaling mediates calcium phosphate-induced pruritus.

45 function, eczematous dermatitis, and chronic pruritus.

46 ing (IASI-S); transepidermal water loss; and pruritus.

47 on (five [7%] of 74 vs three [4%] of 75) and pruritus (0 of 74 vs two [3%] of 75).

48 Es were macular papular eruption (24 [29%]), pruritus (10 [12%]), and hypopigmentation (7 [8%]).

49 anal pain, 11 [12%]; bleeding, 14 [15%]; and pruritus, 10 [11%]).

50 ), rash (19%), nausea (14%), diarrhea (12%), pruritus (12%), and arthralgia (10%).

51 -related adverse events were diarrhea (12%), pruritus (12%), fatigue (7%), and pyrexia (7%).

52 es F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in t

53 atients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients).

54 nt adverse events were mild to moderate oral pruritus (13% for the 6 SQ-HDM group, 20% for the 12 SQ-

55 %] of 25 patients), asthenia (14 [56%]), and pruritus (14 [56%]).

56 tients with primary biliary cholangitis with pruritus, 14 days of ileal bile acid transporter inhibit

57 olic acid was generally well tolerated, with pruritus (149 [77%] patients) and fatigue (63 [33%]) bei

58 most frequently reported adverse events were pruritus (16%; one patient on placebo, four on seladelpa

59 nt-related AEs (most commonly fatigue [25%], pruritus [17%], diarrhea [13%], and rash [13%]), and 10%

60 groups were fatigue (29 [33%] vs 31 [37%]), pruritus (23 [26%] vs 16 [19%]), and rash (16 [18%] vs 1

61 79]), erythema (20 [40%] of 50 [26-55]), and pruritus (41 [82%] of 50 [69-91]) after vaccination by m

62 in the telaprevir phase were fatigue (47%), pruritus (43%), anemia (42%), nausea (37%), rash (35%),

63 l behaviour (6 [6%]), asthenia (6 [6%]), and pruritus (5 [5%]).

64 ted acute dermatitis (36% vs 69%; P < .001), pruritus (54% vs 81%; P < .001), breast pain (55% vs 74%

65 Patients with ZIKV presented with rash and pruritus (69.2% each) more frequently than those with DE

66 en clinical measures (body surface area/BSA, pruritus ADQ, and transepidermal water loss/TEWL) with i

67 vomiting, and one with diarrhoea), then oral pruritus after 6.3% of doses (76 participants) and wheez

68 EP patients experienced less severely scored pruritus after PEBD (ALGS, 100% vs. 9% severe; FIC1, 64%

69 ting data: eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, s

70 Patients with cholestatic disease exhibit pruritus and analgesia, but the mechanisms underlying th

71 4 hours, sometimes associated with erythema, pruritus and blisters.

72 y outcome measures included the reduction of pruritus and burning and/or pain according to a visual a

73 ough not uniformly, result in improvement of pruritus and cholestasis.

74 patient had achieved complete resolution of pruritus and clinical manifestations of the disease, as

75 holestatic, but not other forms of, systemic pruritus and closely correlates with the effectiveness o

76 l insights in signal transmission related to pruritus and discuss pruritogen candidates in cholestasi

77 after ingestion of flatfish and yellowtail, pruritus and dyspnea occurred.

78 ahepatic cholestasis of pregnancy based upon pruritus and elevated serum bile acid concentrations, wi

79 The diagnosis was made by maternal pruritus and elevation of total fasting bile acid (BA) (

80 ed on our hospital because of cough, sputum, pruritus and erythema.

81 Pulsed-dye laser was used for pruritus and erythema; fractional CO2 laser was used for

82 of patient symptoms is paramount, including pruritus and fatigue.

83 Pruritus and health-related quality of life (HRQoL) were

84 These results suggest that pruritus and hyperalgesia in chronic cholestatic BDL rat

85 preterm babies had significantly early onset pruritus and ICP was diagnosed earlier.

86 meta-analysis, UDCA is effective in reducing pruritus and improving liver test results in patients wi

87 asis of pregnancy, characterised by maternal pruritus and increased serum bile acid concentrations, i

88 of proteinase-activated receptor 2-mediated pruritus and MyD88-mediated spongiosis.

89 1 (ECE-1) as a key regulator of ET-1-induced pruritus and neural signaling of itch.

90 pruritic syndromes, including brachioradial pruritus and notalgia paresthetica, have been associated

91 These mechanisms could contribute to pruritus and painless jaundice that occur during cholest

92 s mediating the relationship between chronic pruritus and quality of life are poorly understood.

93 fic liver disease, characterized by maternal pruritus and raised serum bile acids.

94 f life of those affected through symptoms of pruritus and recurrent skin lesions.

95 the COMT gene are associated with post-burn pruritus and scarring.

96 we observed, in all patients, a decrease of pruritus and serum bile acid concentration (BAC) as well

97 molizumab resulted in a greater reduction in pruritus and severity of skin lesions than placebo in pa

98 It has frequently been speculated that pruritus and skin lesions develop after topical exposure

99 An effect of these immunologic treatments on pruritus and the disturbed microbiome in patients with A

100 e duct ligation (BDL) as a model for hepatic pruritus and then to evaluate the contribution of inflam

101 luding vasculogenesis, fibrosis, cholestatic pruritus and tumour progression.

102 ema generally presents with urticaria and/or pruritus and will respond to conventional treatment with

103 rmatitis), neuropathic origin (brachioradial pruritus), and chronic prurigo of nodular type, the latt

104 re attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear differen

105 adverse events included headache, asthenia, pruritus, and diarrhea.

106 attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were

107 t adverse events were asthenia and headache, pruritus, and fatigue.

108 in adults with moderate-to-severe AD, severe pruritus, and inadequate control with topical treatment

109 associated with nivolumab included fatigue, pruritus, and nausea.

110 cancer, fibrosis, inflammation, cholestatic pruritus, and pain.

111 AEs, particularly fever, myalgias, pruritus, and proteinuria/hematuria, occurred in 83% vs

112 Diarrhea, pruritus, and rash were the most common treatment-relate

113 ity of life (QOL) had declined due to severe pruritus, and they had striae and secondary adrenal supp

114 and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) with insulin glargine.

115 maculopapular eruption, lichenoid reactions, pruritus, and vitiligo have been described.

116 The pruritus- and TH2-associated novel cytokine IL-31 induce

117 7-year-old girl developed barking cough and pruritus approximately two hours after eating a frozen C

118 egulate neuropathic pain, but their roles in pruritus are elusive.

119 PONV and pruritus are frequent side-effects of neuraxial morphine

120 acting antiemetics, and strategies to manage pruritus are needed.

121 ological mechanisms leading to chronicity of pruritus are not yet fully understood and it is not know

122 y parameters included EASI, IGA, SCORAD, and pruritus assessment.

123 eading to chronic inflammatory responses and pruritus associated with contact dermatitis.

124 ial of rupatadine for Japanese patients with pruritus associated with skin diseases.

125 were <10%, consisting of minor skin rash and pruritus associated with the patch.

126 Upon reoccurrence of pruritus, ATX activity returned to pretreatment values.

127 Delineation of a progesterone sulfate-TGR5 pruritus axis identifies a therapeutic target for itch m

128 mmon disease in the elderly population, with pruritus being one of the troublesome symptoms.

129 ession and anxiety, fatigue and sleep, pain, pruritus, body image distress, sexual function, work dis

130 These patients usually have fatigue and pruritus, both of which occur independently of disease s

131 A proportion of patients report increased pruritus, but other short-term markers of quality of lif

132 roversion [P = .03], neuroticism [P = .01]), pruritus characteristics (severity [P < .001], duration

133 1 patients in the obeticholic acid developed pruritus compared with nine (6%) of 142 in the placebo g

134 K2330672 administration for 14 days improves pruritus compared with placebo.

135 Within a week after the surgery her pruritus completely resolved.

136 Chronic pruritus (CP) has considerable implications for QOL.

137 een different underlying diseases of chronic pruritus (CP).

138 to treatment was defined as normalization of pruritus, disappearance of jaundice, and alanine aminotr

139 31-neuron axis has been implicated in severe pruritus during atopic skin inflammation, IL-31's neurop

140 complaints including cutaneous flushing and pruritus, dysautonomia, functional gastrointestinal symp

141 50; these additional five skin problems were pruritus, eczema, impetigo, scabies, and molluscum conta

142 city of pruritus with no differences between pruritus entities.

143 in the genital area) and generalized truncal pruritus (especially in patients with diabetes mellitus)

144 grade 3 and 4 events were pain in the vulva, pruritus, fatigue, and headache.

145 commonly reported adverse effects were rash, pruritus, fatigue, and insomnia.

146 eported in at least 10% of the patients were pruritus, fatigue, and nausea.

147 -week group; 12 [20%] in the 16-week group), pruritus (five [8%] in the 12-week group; 14 [23%] in th

148 tch that would subsequently develop ICP from pruritus gravidarum (group 2: ICP n = 41, pruritus gravi

149 om pruritus gravidarum (group 2: ICP n = 41, pruritus gravidarum n = 14).

150 onset of ICP and distinguish it from benign pruritus gravidarum, enabling targeted obstetric care to

151 lestasis of pregnancy (ICP) or due to benign pruritus gravidarum.

152 Patients with moderate to severe pruritus (>=5 of 10 on visual analog scale [VAS]) due to

153 tients had vesiculopustular rash, and fever, pruritus, headache, and lymphadenopathy were also common

154 y paresthesia, arthralgia, myalgia, malaise, pruritus, headache, dizziness, metallic taste, visual di

155 Pruritus, headache, nausea, rash, and dizziness were hig

156 ncy (ICP) affects 1/140 UK pregnancies; with pruritus, hepatic impairment and elevated serum bile aci

157 e) adverse events (including erythema, rash, pruritus, hyperpigmentation, pain, hypopigmentation, and

158 mine-challenged subjects developed immediate pruritus (i.e. within the first 5 min).

159 velopments will likely inform the problem of pruritus in a variety of well-established and emerging c

160 t the long-term usefulness of rupatadine for pruritus in AD.

161 hould be included in the initial therapy for pruritus in all elderly patients.

162 eutic approaches for patients suffering from pruritus in cholestasis.

163 are considered to be important in modulating pruritus in conditions such as chronic kidney disease.

164 There was a trend toward decreased pruritus in FIC1 after IE and GBC.

165 y nerves by directly regulating ET-1-induced pruritus in humans and mice.

166 1/2 pathway as a therapeutic target to treat pruritus in humans.

167 a bullous pemphigoid animal model featuring pruritus in immunocompetent, mature, and largely unmanip

168 ely reduced mast cell numbers and alleviated pruritus in JAK2V617F transgenic mice.

169 thelin 1 (ET-1) evokes histamine-independent pruritus in mammals through activation of its cognate G

170 host range alphaherpesvirus, causes violent pruritus in many different animals, but the mechanism is

171 BAs induce pruritus in mice by co-activation of TGR5 and TRPA1.

172 A1) is involved in BA-evoked, TGR5-dependent pruritus in mice.

173 erleukin-31 (IL-31) is its ability to induce pruritus in pathologic conditions, such as atopic dermat

174 ments in cutaneous signs of inflammation and pruritus in patients with AD, with maximal efficacy obse

175 r to placebo in improving moderate to severe pruritus in patients with PSC and PBC.

176 TCH) was to assess effects of bezafibrate on pruritus in patients with PSC, PBC, and SSC.

177 er inhibitor, a novel class of drug to treat pruritus in PBC.

178 Treatment of pruritus in primary biliary cholangitis is challenging a

179 icant and novel advance for the treatment of pruritus in primary biliary cholangitis.

180 n atopic dermatitis (AD) is the induction of pruritus in the skin.

181 tion, TLR3 knockdown in DRGs also attenuated pruritus in WT mice.

182 after the first intake, she felt a "strange pruritus" in the throat.

183 haracteristics of patients and their chronic pruritus) in multivariate analysis using ItchyQoL scores

184 mination in any case of persistent localized pruritus, in the absence of primary dermatologic causes.

185 erized by intermittent jaundice, intractable pruritus, increased serum bile acid (BA) levels, and nor

186 Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in s

187 en candidate studied so far, correlates with pruritus intensity and responds to therapeutic intervent

188 roliferation, erythema, as well as a form of pruritus, involving cutaneous discomfort.

189 Chronic debilitating pruritus is a cardinal feature of atopic dermatitis (AD)

190 Pruritus is a cardinal symptom of atopic dermatitis, and

191 Persistent pruritus is a common disabling dermatologic symptom asso

192 Pruritus is a common problem among elderly people and, w

193 Chronic pruritus is a common problem with a deleterious effect o

194 Pruritus is a common symptom in patients with cholestati

195 Persistent localized pruritus is a rare manifestation of central nervous syst

196 Pruritus is a sensation that emanates from the skin and

197 Pruritus is a seriously disabling symptom accompanying m

198 round of Atopic Dermatitis (AD) with chronic pruritus is complex.

199 Neuropathic pruritus is infrequently considered but may cause locali

200 V), and the pathophysiology of PV-associated pruritus is unclear.

201 de of special circumstances (eg, intractable pruritus), is undermined by the absence of evidence for

202 Chronic itch, or pruritus, is associated with a wide range of skin abnorm

203 emotional and psychosocial impact of chronic pruritus, it is important to accurately assess and measu

204 NaV1.7-dependent model of histamine-induced pruritus (itch) and additionally in a capsaicin-induced

205 nts with primary biliary cholangitis develop pruritus (itch) during the course of their disease.

206 In humans, pruritus (itch) is a common but poorly understood sympto

207 Pruritus (itch) is a symptom commonly experienced by pat

208 Secondary readouts were changes in pruritus, levels of histamine IL-6, IL-8 and TNF-alpha c

209 opathic pain, fibrotic diseases, cholestatic pruritus, lymphocyte homing, and thrombotic diseases by

210 fter several months of localized intractable pruritus, magnetic resonance imaging of the cervical spi

211 Pruritus may seriously impair quality of life in patient

212 wever, there was no significant reduction in pruritus (MD, 2.1 [95% CI, 0.5 to 3.7] [P = .16]) and in

213 9 to 51.2] [P = .009]) and the VAS score for pruritus (MD, 4.6 [95% CI, 1.5 to 7.7] [P = .005]) and b

214 The mechanism by which the CaP-induced pruritus mediated by the IL-6/p-BTK/p-ERK signaling was

215 mptoms including rash, arthralgia, headache, pruritus, myalgia, and fever.

216 ents (n = 70), the most common of which were pruritus (n = 15; 14.3%), asthenia (n = 14; 13.3%), and

217 erapy (less hematologic toxicity; more rash, pruritus, neuropathy, and alopecia).

218 SCORAD, Dermatology Life Quality Index, and pruritus numeric rating scale (7-day mean) scores versus

219 ersus vehicle, with improvement in pruritus (pruritus numeric rating scale) observed as early as 24 h

220 f body surface area affected >=10%, and Peak Pruritus Numerical Rating Scale score >=4) with a bodywe

221 dverse events related to Opra Kappa included pruritus, observed in a subset of individuals.

222 A transient worsening of erythroderma and pruritus occurred in 53% of patients with SS.

223 Pruritus occurred more frequently with the active regime

224 Pruritus occurs frequently in patients with polycythemia

225 Acute pruritus occurs in various disorders.

226 UDCA was associated with total resolution of pruritus (odds ratio [OR], 0.23; 95% confidence interval

227 resented with signs of localized intractable pruritus of 6 months' duration on the left side of the n

228 increased serum ATX levels are specific for pruritus of cholestasis, but not pruritus of uremia, Hod

229 ly represents a novel therapeutic target for pruritus of cholestasis.

230 Percentage of pruritus of ear and throat was significantly low in pedi

231 nt years, a major role for IL-31 in allergic pruritus of humans, monkeys, dogs, and mice was acknowle

232 eristics, pathophysiology, and mechanisms of pruritus of major systemic underlying diseases, includin

233 he need to differentiate whether gestational pruritus of the skin is an early symptom of intrahepatic

234 dered in children with intractable localized pruritus of unknown etiology of the head and neck or upp

235 pecific for pruritus of cholestasis, but not pruritus of uremia, Hodgkin's disease, or atopic dermati

236 stration, she developed a heat sensation and pruritus on her neck, with flushing, abdominal pains, br

237 ignificantly influence the impact of chronic pruritus on quality of life demonstrates the complex nat

238 Factors that mediated the impact of chronic pruritus on quality of life were demographic characteris

239 at least 7 for the worst daily intensity of pruritus on the numerical rating scale (scores range fro

240 nge from baseline in the mean peak score for pruritus on the numerical rating scale at week 4.

241 no symptoms of early satiety, night sweats, pruritus, or erythromelalgia.

242 osing cholangitis include fatigue, jaundice, pruritus, or steatorrhoea.

243 11% to >=50% reduction of severe or moderate pruritus (P = .003).

244 a "4P" Scar Scale (UNC4P), which rates pain, pruritus, paresthesias, and pliability.

245 ema Area and Severity Index (EASI), the peak pruritus (PP) numeric rating scale (NRS), and the Invest

246 symptoms versus vehicle, with improvement in pruritus (pruritus numeric rating scale) observed as ear

247 5% of patients in either group were fatigue, pruritus, rash, and diarrhea.

248 igue, nausea, headache, dizziness, insomnia, pruritus, rash, and vomiting.

249 tic approach for patients with chronic liver pruritus refractory to conventional treatments.

250 late in life and is characterized by intense pruritus, resulting in a phenotype resembling acquired i

251 and EASI-75 (RR 3.09; 95% CI 2.45 to 3.89), pruritus (RR 2.96; 95% CI 2.37 to 3.70), rescue medicati

252 the investigator's global assessment score, pruritus, safety assessments, serum biomarker levels, an

253 ulgaris, bacterial skin diseases, urticaria, pruritus, scabies, cellulitis, and alopecia areata were

254 The mean score at baseline total pruritus score (TPS) was 4.682.

255 severe baseline symptom from the following: pruritus score of 9 or more, eight or more flushes per w

256 The initial pruritus score on the numerical rating scale was 8.4 in

257 At week 4, the peak pruritus score on the numerical rating scale was reduced

258 SCOring AD, Patient-Oriented Eczema Measure, pruritus score, sleep score, Dermatology Life Quality In

259 estigator's global assessment (P<0.001); and pruritus scores decreased (indicating a reduction in itc

260 The key outcomes include improvement in pruritus scores evaluated on a numerical rating scale an

261 The secondary endpoints were changes in pruritus scores measured using the 0 to 10 numerical rat

262 bal Assessment (IGA) scores of 3 or greater, pruritus scores of 5 or greater (0- to 10-point scale),

263 and AD cohorts, possibly contributing toward pruritus seen in both groups.

264 nts (68%), causing tenderness or discomfort, pruritus, sensitivity to touch, and/or discomfort with b

265 vents, and demonstrated efficacy in reducing pruritus severity.

266 Clinical symptoms were heterogeneous: pruritus sine materia (no primary skin lesions), eczemat

267 and family quality of life caused by intense pruritus, sleep disruption, dietary and nutritional conc

268 Patient-reported pruritus subscores obtained from SCORAD were reduced wit

269 e, Na(V)1.7 and 1.9 may represent targets in pruritus therapy.

270 t frequent reported adverse events were oral pruritus, throat irritation, and nasopharyngitis.

271 e peripheral itch sensory neurons and elicit pruritus through MRGPRs, a family of G-protein coupled r

272 Other symptoms included plugging, pruritus, tinnitus, pain, and bleeding.

273 ce, with clinical symptoms ranging from oral pruritus to fatal anaphylactic reaction.

274 oing hemodialysis who had moderate-to-severe pruritus to receive either intravenous difelikefalin (at

275 Little evidence supports pruritus treatment, limiting therapeutic possibilities a

276 ognized are postherpetic itch, brachioradial pruritus, trigeminal trophic syndrome, and ischaemic str

277 increased the risk of arterial hypotension, pruritus, urinary retention, and motor blockade.

278 placebo) and evening (P = .007) intensity of pruritus (VAS) and improved the validated 5D-Itch questi

279 = .03 vs placebo) correlating with improved pruritus (VAS, P = .01) suggesting reduced biliary damag

280 The primary end point was >=50% reduction of pruritus (VAS; intention-to-treat).

281 igns (objective SCORAD), symptoms (POEM, VAS pruritus, VAS sleeping problems) and previous treatment

282 the placebo group were arthralgia, diarrhea, pruritus, vomiting, and chest pain.

283 as defined as 20 or more nodules, and severe pruritus was defined as a mean score of at least 7 for t

284 Acute pruritus was induced by a comprehensive panel of prurito

285 Moderate to severe pruritus was more common in patients receiving cilofexor

286 Pruritus was more common with obeticholic acid than with

287 Application site pruritus was the most common treatment-related adverse e

288 Pruritus was the principal adverse event; incidence valu

289 Alopecia, injection site erythema, and pruritus were 13%, 27%, and 10%, respectively.

290 Rates of grade 2 or 3 pruritus were 14% with 100 mg, 20% with 30 mg, and 40% w

291 The incidence and severity of pruritus were lowest among patients who received 10 mg/d

292 A total of 76 adults with chronic pruritus were recruited.

293 physician-reported scar appearance and pain/pruritus were significantly improved (P < 0.01).

294 ient injection-site reactions (eg, erythema, pruritus) were the most frequent IMA901-related side-eff

295 certain systemic diseases can cause chronic pruritus, which has a significant effect on the patient'

296 rrent study, we found frequent occurrence of pruritus with aged JAK2V617F transgenic mice and further

297 Uremic pruritus with elevated levels of calcium phosphate (CaP)

298 which might contribute to the chronicity of pruritus with no differences between pruritus entities.

299 ere was a 3-point reduction (scale, 1-10) in pruritus with ZPL-3893787, but there was a similar reduc

300 history of a penicillin allergy, symptoms of pruritus without rash, or remote (>10 years) unknown rea